Clinical Trial Detail

NCT ID NCT04274907
Title A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors AbbVie
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab + Venetoclax

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST